Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases

A Phase I Single Centre 2-part Open Study to Assess the Safety and Tolerability of AZD2171 Following Single and Multiple Oral Doses in Patients With Advanced Solid Malignant Tumors and Liver Metastases

Single centre recruiting approximately 80 patients who are given a rising single, followed by multiple, ascending oral dose of AZD2171, assessing the safety and tolerability of AZD2171 in patients with solid tumors and metastatic liver disease.

Inclusion Criteria:

• Provision of written informed consent
• Male/female, 18 yr or over
• WHO status 0-2
• Refractory advanced solid tumor

Exclusion Criteria:

• Radiotherapy within 4 weeks of starting AZD2171 treatment
• Low haemoglobin level
• Low platelet or neutrophil counts